Hatabah Dunia, Gupta Sneh Lata, Mantus Grace, Sullivan Patrick, Heilman Stacy, Camacho-Gonzalez Andres, Leake Deborah, Le Mimi, Griffiths Mark, Norwood Carson, Shih Samuel, Korman Rawan, Maziashvili Giorgi, Rees Chris A, Benedit Laura, Wynn Bridget A, Suthar Mehul, Vos Miriam B, Wrammert Jens, Morris Claudia R
Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA.
Vaccines (Basel). 2025 Feb 7;13(2):163. doi: 10.3390/vaccines13020163.
Vaccines against COVID-19 target the spike protein. There is minimal information on longitudinal COVID-19 immune profiling in recovered versus naïve and vaccinated versus non-vaccinated healthcare workers (HCWs). This is a prospective longitudinal observational cohort of pediatric HCWs (pHCWs) conducted during 2020-2022 at an academic center, exploring the impact of COVID-19 vaccination on immunoglobulin G (IgG) antibody titers over time and cross-reactivity with other coronaviruses, including SARS-CoV-1, MERS-CoV, and seasonal coronaviruses (HCoV-HKU1 and HCoV-OC43). A total of 642 pHCWs initially enrolled, and 337 participants had repeat IgG titers measured post-vaccine and post-booster. Most participants were female, median age range of 31-40 years. Anti-spike was higher in all vaccinated individuals versus non-vaccinated ( < 0.0001) and naïve versus infected ( < 0.0001). A single dose of vaccine was sufficient to attain maximum titers in recovered participants versus naïve who received both doses of vaccine. Anti-spike titers dropped significantly at 9 months after the primary series, whereas sustained anti-spike titers were observed at 9 months post-booster. All vaccinated pHCWs developed antibodies to spike. COVID-19 infection and/or vaccination yielded antibodies that cross-reacted to SARS-CoV-1, MERS-CoV, HCoV-HKU1, and HCoV-OC43. Anti-spike titers were more durable post-booster compared to the primary series. Longitudinal immune profiling of COVID-19 responses provides vital data to shape public health policies, optimize vaccine strategies, and strengthen pandemic preparedness.
针对新冠病毒的疫苗以刺突蛋白为靶点。关于康复医护人员与未感染且未接种疫苗的医护人员、接种疫苗的医护人员与未接种疫苗的医护人员的新冠病毒纵向免疫谱分析的信息极少。这是一项于2020年至2022年在一个学术中心对儿科医护人员(pHCWs)进行的前瞻性纵向观察队列研究,探讨新冠病毒疫苗接种对免疫球蛋白G(IgG)抗体滴度随时间的影响以及与其他冠状病毒(包括SARS-CoV-1、MERS-CoV和季节性冠状病毒HCoV-HKU1及HCoV-OC43)的交叉反应性。最初共招募了642名儿科医护人员,337名参与者在接种疫苗后和接种加强针后进行了重复IgG滴度测量。大多数参与者为女性,年龄中位数在31至40岁之间。所有接种疫苗的个体的抗刺突抗体水平均高于未接种疫苗的个体(<0.0001),康复个体的抗刺突抗体水平高于未感染个体(<0.0001)。对于康复参与者,单剂疫苗就足以达到与接种两剂疫苗的未感染参与者相同的最高滴度。初次接种系列后9个月,抗刺突抗体滴度显著下降,而在接种加强针后9个月观察到抗刺突抗体滴度持续存在。所有接种疫苗的儿科医护人员都产生了针对刺突的抗体。新冠病毒感染和/或疫苗接种产生了与SARS-CoV-1、MERS-CoV、HCoV-HKU1和HCoV-OC43发生交叉反应的抗体。与初次接种系列相比,接种加强针后抗刺突抗体滴度更持久。新冠病毒反应的纵向免疫谱分析为制定公共卫生政策、优化疫苗策略以及加强大流行防范提供了重要数据。